Plain-English translation of NCT07084883 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing iPredict, an artificial intelligence system designed to detect early signs of age-related macular degeneration (AMD) using simple eye photographs. The AI system analyzes these photos automatically to identify people at risk of losing vision. Researchers want to confirm that the system works as well as eye specialists do when looking at detailed eye imaging.
Currently, there is no good way to screen large numbers of people for early AMD in regular doctor's offices, even though catching it early could prevent blindness and help people avoid depression, falls, and loss of independence. This medication could help doctors identify people who would benefit from vitamin supplements that have been shown to slow disease progression.
You likely qualify if…
You likely don't qualify if…
You would visit your primary care doctor's office or an eye doctor's office where a special camera will take non-dilated photos of your eyes—no drops needed, just like a regular eye photo. These photos are then securely sent to a computer system that analyzes them using artificial intelligence. Researchers will compare the AI's findings to detailed eye scans to make sure the system is accurate.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Collaborators
National Institutes of Health (NIH), National Eye Institute (NEI)
Enrollment target
~1,076 participants
Started
August 2024
Primary completion
July 2027
Age range
50 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alauddin Bhuiyan
iHealthScreen Inc
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.